Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA (MRK)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
07/13/2018 07/16/2018 07/17/2018 07/18/2018 07/19/2018 Date
85.62(c) 85.62(c) 85.5(c) 85.5(c) 85.82 Last
329 701 304 745 314 489 298 764 169 921 Volume
+0.63% 0.00% -0.14% 0.00% +0.37% Change
More quotes
Financials (EUR)
Sales 2018 14 794 M
EBIT 2018 2 857 M
Net income 2018 2 154 M
Debt 2018 7 526 M
Yield 2018 1,47%
Sales 2019 15 120 M
EBIT 2019 3 053 M
Net income 2019 1 877 M
Debt 2019 5 318 M
Yield 2019 1,55%
P/E ratio 2018 16,26
P/E ratio 2019 18,26
EV / Sales2018 1,26x
EV / Sales2019 1,09x
Capitalization 11 098 M
More Financials
Company
Merck KGaA engages in the manufacture of pharmaceutical and chemical products.It operates through the following sectors: Healthcare, Life Science, and Performance Materials.The Healthcare sector discovers, develops, and manufactures prescription medicines used to treat cancer, multiple sclerosis,... 
Sector
Pharmaceuticals
Calendar
08/09Earnings Release
More about the company
Surperformance© ratings of Merck KGaA
Trading Rating : Investor Rating :
More Ratings
Latest news on MERCK KGAA
04:30aMERCK : Vyriad Announces Collaboration with Merck KGaA, Darmstadt, Germany, and ..
AQ
07/17MERCK : Darmstadt, Germany, Announces Future Insight Prize of up to € 1 Million ..
PU
07/16Startup Producing Cell-Grown Meat Raises New Funding
DJ
07/09Catalent Signs Agreement to Acquire Juniper Pharmaceuticals, Inc
AQ
07/03ABCAM : collaborates with Merck to produce anti-PD-L1 antibody clone for global ..
AQ
07/03DIC : Germany's Merck sees performance materials unit turning corner in 2020
RE
07/03MERCK : Updates Targets for Performance Materials Unit
DJ
07/03MERCK : Performance Materials Gives Strategy Update
PU
06/27MERCK : Novasep launches Merck-tested BioSC Pilot for batch and continuous chrom..
AQ
06/26FDA slaps new bladder cancer limits on Merck`s Keytruda, Roche`s Tecentriq
AQ
More news
Sector news : Specialty & Advanced Pharmaceuticals
05:55aBarclays appoints Campili as vice chairman for healthcare banking
RE
02:48aNOVARTIS : Freezes Its Drug Prices -- WSJ
DJ
02:16aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
07/18Novartis hints at 2018 outlook hike despite drug price freeze
RE
07/18Novartis hints at 2018 outlook hike despite drug price freeze
RE
More sector news : Specialty & Advanced Pharmaceuticals
4-Traders Strategies on MERCK KGAA 
MERCK KGAA - 2017
The downward trend should continue
SELL
MERCK KGAA - 2016
Towards the breakout of a major resistance level
BUY
More Strategies
Latest Tweets
01:12aHims, building a hipster brand around drugs that Pfizer and Merck spent years.. 
07/18Hyleukin-7 Selected as a Korea Drug Development Fund (KDDF) Project for Combi.. 
07/18Hyleukin-7 Selected as a Korea Drug Development Fund (KDDF) Project for Combi.. 
07/18DW's Gerhard Elfers talks to Merck's CEO Stefan Oschmann about the importance..
1
07/18Merck joins push to develop lab-grown beef  
More tweets
Qtime:158
News from SeekingAlpha
07/15WEEK IN REVIEW : Tasly Biopharma Completes Pre-IPO Round At $1.9 Billion Valuati.. 
07/03MERCK KG&A (MKGAY) Performance Materials Strategy Update - Slideshow 
07/02FDA withdraws draft guidance related to biosimilar development 
06/13YOUR DAILY PHARMA SCOOP : Tetraphase Positive Data, MediWound In Phase 3, Allerg.. 
06/133 THINGS IN BIOTECH, JUNE 12 : MET Targeting Gets On Your Radar 
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 96,4 €
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA-4.74%12 859
ABBVIE-2.39%151 404
KYOWA HAKKO KIRIN CO LTD-1.49%11 440
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD101.03%11 422
JAZZ PHARMACEUTICALS PLC30.75%10 586
CONVATEC GROUP-0.78%5 349